Document is current

Article History

Accepted: 27 November 2022

First Online: 24 January 2023

Declarations

:

: Abbott contracted IQVIA for the conduct of this study. Prof. Prieto-Alhambra receives funding from the UK National Institute for Health Research in the form of a Senior Research Fellowship, and as part of the Oxford National Institute for Health Research Biomedical Research Centre. Prof. Giustino Varrassi had a contract with Abbott International, as a consultant for scientific projects. He is also a consultant for scientific projects with Dompé Farmaceutici and Menarini Group.

: All authors have completed the ICMJE disclosure form at ExternalRef removed and declare the following interests: Dani Prieto-Alhambra receives funding from the UK National Institute for Health Research in the form of a senior research fellowship and from the Oxford National Institute for Health Research Biomedical Research Centre. Junqing Xie receives the Clarendon Fund and Jardine scholarship (University of Oxford) to support her DPhil study. Dani Prieto-Alhambra’s research group has received research grants from the European Medicines Agency, the Innovative Medicines Initiative, Amgen, Chiesi and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, AstraZeneca and UCB Biopharma.

: These assets are de-identified, commercially available data products that could be purchased and licensed by any researcher. The collection and de-identification of these data assets is a process that is commercial intellectual property and not privileged to the data licensees and the co-authors on this study. Licensees of these data have signed data use agreements with the data vendors that detail the usage protocols for running retrospective research on these databases. All analyses performed in this study were in accordance with data use agreement terms as specified by the data owners. As these data are deemed commercial assets, there is no institutional review board applicable to the usage and dissemination of these result sets or required registration of the protocol with additional ethics oversight. Compliance with data use agreement terms, which stipulate how these data can be used and for what purpose, is sufficient for the licensing commercial entities.

: Not applicable.

: Not applicable.

: Patient-level data cannot be shared without approval from data custodians owing to local information governance and data protection regulations. Additional summary data, analytical code and detailed definitions of algorithms for identifying the events are available from the corresponding author on reasonable request to access the GitHub repository.

: Not applicable.

: JQ-X, DP-A, SS, CT and GV conceived the study and contributed to the study design. JQ-X, JB and JA conducted the statistical analyses. JQ-X and DP-A interpreted the results and wrote the manuscript. All authors contributed to writing the manuscript, approved the final version and had final responsibility for the decision to submit for publication. The lead authors (JQ-X and JB) affirm that this manuscript is an honest, accurate and transparent account of the study being reported, that no important aspects of the study have been omitted and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. DP-A is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.